Baloxavir marboxil: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug pregnan...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: [[Antiviral]] | ||
*Dosage Forms: | *Dosage Forms: 20 mg, 40 mg tab | ||
*Routes of Administration: | *Routes of Administration: PO | ||
*Common Trade Names: | *Common Trade Names: Xofluza | ||
==Indications== | |||
* [[Influenza]] | |||
==Adult Dosing== | ==Adult Dosing== | ||
* 40-79.9 kg: 40 mg PO x1 | |||
**Start within 48 hours of symptom onset | |||
**Avoid co-administration with dairy products, calcium supplements | |||
*>80 mg: 80 mg PO x1 | |||
**Start within 48 hours of symptom onset | |||
**Avoid co-administration with dairy products, calcium supplements | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Approved for use in pediatric patients 12 and older | |||
* 40-79.9 kg: 40 mg PO x1 | |||
**Start within 48 hours of symptom onset | |||
**Avoid co-administration with dairy products, calcium supplements | |||
*>80 mg: 80 mg PO x1 | |||
**Start within 48 hours of symptom onset | |||
**Avoid co-administration with dairy products, calcium supplements | |||
==Special Populations== | ==Special Populations== | ||
*[[Pregnancy Category]]: Not assigned (insufficient data) | |||
* | *[[Lactation risk]]: Avoid use while breastfeeding | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult and Pediatric: | ||
* | **CrCl>50: no adjustment | ||
**CrCl<50 or HD/PD: not defined | |||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*Adult: | *Adult and Pediatric: | ||
* | **Child-Pugh Class A or B: no adjustment | ||
**Child-Pugh Class C: not defined | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Pregnancy | |||
*Breastfeeding | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*[[Anaphylaxis]] | |||
*[[Angioedema]] | |||
*[[Erythema multiforme]] | |||
*[[Urticaria]] | |||
===Common=== | ===Common=== | ||
*Nausea (Especially in older patients) | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 79.1 hours | ||
*Metabolism: | *Metabolism: liver (CYP450) | ||
*Excretion: | *Excretion: Feces (predominant), urine<ref>Baloxavir marboxil [monograph]. Epocrates Version. 20.2 [iPhone]. Epocrates, Inc, San Francisco, CA. Available from https://online.epocrates.com/. Accessed March 18, 2020.</ref> | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Inhibits viral polymerase acidic protein endonuclease activity, which inhibits viral replications | |||
==Comments== | ==Comments== | ||
| Line 48: | Line 66: | ||
==See Also== | ==See Also== | ||
*[[Influenza]] | |||
*[[Antiviral]] | |||
*[[Tamiflu]]/[[Oseltamivir]] | |||
==References== | ==References== | ||
Latest revision as of 14:49, 18 March 2020
Administration
- Type: Antiviral
- Dosage Forms: 20 mg, 40 mg tab
- Routes of Administration: PO
- Common Trade Names: Xofluza
Indications
Adult Dosing
- 40-79.9 kg: 40 mg PO x1
- Start within 48 hours of symptom onset
- Avoid co-administration with dairy products, calcium supplements
- >80 mg: 80 mg PO x1
- Start within 48 hours of symptom onset
- Avoid co-administration with dairy products, calcium supplements
Pediatric Dosing
- Approved for use in pediatric patients 12 and older
- 40-79.9 kg: 40 mg PO x1
- Start within 48 hours of symptom onset
- Avoid co-administration with dairy products, calcium supplements
- >80 mg: 80 mg PO x1
- Start within 48 hours of symptom onset
- Avoid co-administration with dairy products, calcium supplements
Special Populations
- Pregnancy Category: Not assigned (insufficient data)
- Lactation risk: Avoid use while breastfeeding
Renal Dosing
- Adult and Pediatric:
- CrCl>50: no adjustment
- CrCl<50 or HD/PD: not defined
Hepatic Dosing
- Adult and Pediatric:
- Child-Pugh Class A or B: no adjustment
- Child-Pugh Class C: not defined
Contraindications
- Allergy to class/drug
- Pregnancy
- Breastfeeding
Adverse Reactions
Serious
Common
- Nausea (Especially in older patients)
Pharmacology
- Half-life: 79.1 hours
- Metabolism: liver (CYP450)
- Excretion: Feces (predominant), urine[1]
Mechanism of Action
- Inhibits viral polymerase acidic protein endonuclease activity, which inhibits viral replications
Comments
Only approved for patients >12 years old and >40kg in weight, no current safety data exists for pregnancy and breastfeeding.[2] More expensive but one time dosing. Genentech, its creator, states a recent phase III trial has shown it to be effective for prophylaxis but not currently FDA indicated for this.[3]
See Also
References
- ↑ Baloxavir marboxil [monograph]. Epocrates Version. 20.2 [iPhone]. Epocrates, Inc, San Francisco, CA. Available from https://online.epocrates.com/. Accessed March 18, 2020.
- ↑ https://www.cdc.gov/flu/treatment/baloxavir-marboxil.htm
- ↑ https://www.gene.com/download/pdf/xofluza_prescribing.pdf